Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones

ARVINAS, INC.

Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.
Novartis pays $150M upfront; Arvinas eligible for up to $1.01B in development, regulatory, and commercial milestones plus tiered royalties.
Asset purchase includes Arvinas' preclinical AR-V7 program sold to Novartis.
Novartis assumes full responsibility for global clinical development and commercialization of ARV-766.
Closing subject to HSR antitrust waiting period expiration or termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).

Action: entry
Agreement: license
Counterparty: Novartis Pharma AG
Value: $150.0 million upfront, up to $1.01 billion in milestones
Effective: 2024-04-10

Exact text from the filing

On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-24-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.